CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has selected its next drug, designated DK049, for clinical development in 2016.  DK049 was created using CytRx’s novel LADR™ (Linker-Activated Drug Release) technology that allows the drug to bind to albumin in the body’s bloodstream and controls its release at the site of the tumor. The LADR™ technology used with DK049 employs a two-stage linker that utilizes both pH sensitivity and acts enzymatically to allow release of its cytotoxic drug payload which extends the duration of exposure in tumors. Prolonged inhibition of tumor growth has been demonstrated in human tumor xenograft models of pancreatic cancer, non-small cell lung cancer and ovarian cancer at doses that lack apparent toxicity.  As an example of the LADR™ technology’s capability, human ovarian tumor xenograft models received 85% less drug than a known chemotherapy comparator, yet at the end of the study, DK049-treated tumors were an average 13 times smaller than the chemotherapy-treated animals.  These data have been submitted for presentation at the American Association of Cancer Research Annual Meeting in April 2016. Additionally, CytRx has applied for patents for both its LADR™ technology and DK049 itself.

“We believe that our LADR™ technology is the next advancement in linker-controlled drug release to be used with both antibody-drug conjugates and albumin-binding approaches, ” commented Dr. Felix Kratz, Vice President of Drug Discovery at CytRx. “The ability to adjust the structure and composition of our linkers allows CytRx to attach a variety of lethal agents that include modified standard chemotherapies as well as highly potent agents currently used in antibody-drug conjugates.”

“In only its first year, our Drug Discovery Group has created a technology that is capable of providing CytRx with a clinical pipeline for years to come,” said Steven A. Kriegsman, Chairman and CEO of CytRx Corporation. “Their creation of DK049 was accomplished very rapidly due to the intelligent drug design and experience of Dr. Kratz’s group. We are confident that their progress with the LADR™ technology will be a key value driver for CytRx in the future.” (Original Source)

Shares of Cytrx closed last Friday at $2.94, down $0.06 or -2.00%. CYTR has a 1-year high of $5.42 and a 1-year low of $1.98. The stock’s 50-day moving average is $3.00 and its 200-day moving average is $3.09.

On the ratings front, Oppenheimer analyst Christopher Marai reiterated a Buy rating on CYTR, with a price target of $10, in a report issued on November 5. The current price target represents a potential upside of 240.1% from where the stock is currently trading.

According to, Marai has a total average return of 24.7%, a 61.2% success rate, and is ranked #28 out of 3645 analysts.

CytRx Corp is a biopharmaceutical research and development company specializing in oncology. Its oncology pipeline includes three clinical-stage drug candidates in various stages of development: Aldoxorubicin, Tamibarotene, and Bafetinib.